2 months ago
16
REDWOOD CITY, Calif., Feb. 06, 2025 (GLOBE NEWSWIRE) -- Ashvattha Therapeutics ("Ashvattha”), a clinical-stage company advancing a new class of nanomedicine therapeutics that traverse tissue barriers to selectively target and reprogram activated cells in regions of inflammation, today announced upcoming presentations at Angiogenesis, Exudation, and Degeneration 2025 virtual meeting on February 8, 2025 and the BIO CEO & Investor Conference being held on February 10-11, 2025 at the New York Marriott Marquis in New York City.
Dr. Michael Singer will present interim Phase 2 results for migaldendranib (MGB), Ashvattha's investigational subcutaneous treatment for wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME). The ongoing Phase 2 study is evaluating MGB administered subcutaneously every 2 or 4 weeks for up to 40 weeks after a single intravitreal injection of aflibercept.
Presentation Details:
Angiogenesis, Exudation, and Degeneration 2025
- Presentation Title: Subcutaneous Migaldendranib (MGB) for the Treatment of Neovascular Age-Related Macular Degeneration and Diabetic Macular Edema: 9 Month Results of Chronic Dose Phase 2 Study
- Presentation Time: February 8 at 1:55 PM ET
- Location: Virtual
- Presenter: Michael Singer, MD, Clinical Professor of Ophthalmology, University of Texas Health Science Center San Antonio and Director of Clinical Research, Medical Center Ophthalmology San Antonio
BIO CEO
Get the latest news
delivered to your inbox
Sign up for The Manila Times newsletters
By signing up with an email address, I acknowledge that I have read and agree to the Terms of Service and Privacy Policy.
- Presentation Title: Advancing a New Class of Therapies to Reprogram Activated Macrophages and Microglia Across Multiple Diseases
- Presentation Time: February 10 at 9:45 AM ET
- Location: Marriott Marquis, Plymouth Conference Room, Sixth Floor
- Presenter: Jeffrey L. Cleland, PhD, Chairman, CEO & President, Ashvattha
The presentations follow Ashvattha's recent announcement of up to $50 million in additional Series B financing led by Tribe Capital to advance the company's hydroxyl dendrimer therapeutic (HDT) platform.
For more information regarding the conferences, please visit their respective websites:
About Ashvattha Therapeutics
Ashvattha Therapeutics is advancing a new class of clinical-stage nanomedicine therapeutics that traverse tissue barriers to selectively target and reprogram activated cells only in regions of inflammation. Our targeted nanomedicine approach seeks to redefine precision medicine, empowering a new standard of care across ophthalmology, neurology, and inflammation. Ashvattha Therapeutics was founded by Kannan Rangaramanujam, Sujatha Kannan, and Jeff Cleland and incubated by Natural Capital. For more information, visit: www.avttx.com
Media
ICR Healthcare
Investor Relations
Aman Patel, CFA & Adanna G. Alexander, PhD
